Treanor, MD - Prof Med Gagneur, MD, PhD - Professor

112 SCIENTIFIC SESSIONS September 9-12 | ------------------------------------------------------------------------ 114 G Slide Session Vaccines: Innovations, Impact and Safety Monday, 1:30 p.m.–4:00 p.m. . . . . . . . . . . . . . . . . . . . Room 121 UAN: 0391-9999-12-086-L04-P Moderators: Jan Bonhoeffer, MD - Assistant Professor Infectious Disease and Vaccines, Univ. Children’s Hosp., Basel, Switzerland. Penina Haber, MPH - Epidemiologist Immunization safety, CDC, Atlanta, GA. Objectives: Upon the completion of this Slide Session, the participant should be able to: Highlight new vaccine developments; Provide updated information on vaccine impact and safety; and Discuss the impact of newer vaccines. Presentations: 1:30 p.m. G-1047 Antibody Persistence and the Effect of a Booster Dose Given 5, 10 or 15 Years After Vaccination With a Recombinant Hepatitis B Vaccine V. Gilca, MD, PhD - Medical Epidemiologist 1,2,3 , N. Boulianne, MS - Medi- cal Epidemiologist 1,2,3 , M. Dionne, MD - Scientific Director 1,2,3 , P. D. Wals, MD, PhD - Medical Epidemiologist 1,2,3 , G. D. Serres, MD, PhD - Medical Epidemiologist 1,2,3 ; 1 Quebec Publ. Hlth. Inst., Quebec, Canada, 2 Laval Univ. Res. Hosp. Ctr., Quebec, Canada, 3 Laval Univ., Quebec, Canada. 1:45 p.m. G-1048 Safety and Immunogenicity of an Intramuscular Bivalent Norovirus VLP Vaccine J. J. Treanor, MD - Prof Med 1 , S. E. Frey, MD - Prof Med 2 , R. Gormley, MD, PhD - Investigator 3 , R. L. Atmar, MD - Prof Med 4 , D. Topham, PhD - Prof Microbiol Immunol 1 , W. Chen, MD - Assist Prof Med 5 , J. Ferreira, ScM - Biostatistician 6 , R. Bargatze, PhD - CSO 7 , C. Richard- son, PhD - VP RD 8 , P. Mendelman, MD - CMO 8 ; 1 Univ. of Rochester, Rochester, NY, 2 St. Louis Univ. Sch. of Med., St. Louis, MO, 3 Navy Med. Res. Ctr., Silver Springs, MD, 4 Baylor Coll. of Med., Houston, TX, 5 Univ. of Maryland Sch. of Med., Baltimore, MD, 6 Emmes Corporatiopn, Rockville, MD, 7 Ligocyte Pharmceuticals, Bozeman, MT, 8 Ligocyte Pharmaceuticals, Bozeman, MT. 2:00 p.m. G-1049 Nasopharyngeal Carriage in Healthy Children Before and After 13-valent Pneumococcal Conjugate Vaccine Implementation R. Cohen, MD - Pediatric Infectious Disease Specialist, Scientific Direc- tor of a Research Institute on Pediatric Community-Acquired Infections ACTIV 1 , C. Levy, MD - Research MD 1 , E. Bingen, PhD - Professor Microbiology 2 , S. Béchet, MSc - Biostatistician 1 , C. Bensoussan-Ambacher, MD - Pediatrician 3 , F. Corrard, MD - Pediatrician 1 , E. Varon, MD - Mi- crobiologist 4 ; 1 Activ, Saint Maur des Fossés, France, 2 Denis Diderot Univ., Paris, France, 3 AFPA, Vence, France, 4 CNRP APHP, Paris, France. 2:15 p.m. G-1050 Rapid Reduction in the Incidence of Culture-Positive Non- susceptible Streptococcus pneumoniae NSSP Otitis Media AOM Following Introduction of Pneumococcal Conjugate Vaccines PCVs in Southern Israel R. Dagan, MD - Professor, N. Givon-Lavi, PhD - Lecturer, E. Leibovitz, MD - Professor, S. Raiz, MD - Doctor, D. Greenberg, MD - Professor; Ben- Gurion Univ. of the Negev and Soroka Univ. Med. Ctr., Beer-Sheva, Israel. 2:30 p.m. G-1051 Promoting Vaccination at Birth Improves Vaccination Coverage

A. Gagneur, MD, PhD - Professor

1 , A. Farrands, Msc - Research Assistant 2 , T. Lemaitre, Msc - Research Assistant 2 , G. Petit, MD, PhD - Professor 1 ; 1 Univ. of Sherbrooke, Sherbrooke, Canada, 2 Clinical Res. Ctr. CHU Sher- brooke, Sherbrooke, Canada. 2:45 p.m. G-1052 Safety of Live Attenuated Influenza Vaccine in Adults: U.S., Vaccine Adverse Event Reporting System VAERS P. Haber, MPH - Epidemilogist, P. Moro, MD - Medical Epidemilogist, K. Broder, MD - Medical Epidemilogist, P. Lewis, MSPH - Statistician, C. Vellozzi, MD, MPH - Medical Epidemilogist; CDC, Atlanta, GA. 3:00 p.m. G-1053 Safety and Immunogenicity of a Recombinant Hemagglutinin rHA Pandemic H5N1 Influenza Vaccine J. J. Treanor, MD - Professor of Medicine